Xaira Therapeutics, an AI-enabled drug discovery and development company, announced its launch with more than $1 billion in capital.
The biotechnology company is a joint incubation by ARCH Venture Partners and Foresite Labs, the lead investors in the funding round.
Lux Capital, Two Sigma Ventures, F-Prime, Rsquared, SV Angel, Menlo Ventures, Sequoia Capital, NEA, the Parker Institute for...
Israel-based AION Labs, an AI-enabled drug discovery partnership between global pharma and tech companies, announced the launch of a new startup, TenAces.
TenAces will utilize AI, integrating biology and machine learning algorithms, to discover molecular glue therapies to enhance targeted protein degradation.
Molecular glues are protein-binding small molecules that change two protein...
German pharmaceutical company Boehringer Ingelheim and tech giant IBM are teaming up to harness the power of genAI and foundation models to further biologic drug discovery.
The partnership leverages IBM’s foundation model technologies, consisting of pre-trained, large-scale neural network architectures, to accelerate the identification of novel antibodies vital for therapeutic development.
These...
Tel Aviv-based AI-enabled computational protein engineering platform Scala Biodesign announced its launch today with $5.5 million in seed funding.
The round was led by TLV Partners, an Israeli venture capital firm that invests in early-stage startups.
WHAT IT DOES
Scala's computational method utilizes AI, physics-based modeling and biological data analysis to engineer and improve proteins for...
Causaly, a tech company using AI to interpret large datasets and literature, announced it closed a $60 million Series B round led by ICONIQ Growth.
Marathon Venture Capital, Index Ventures, Pentech Ventures, EBRD and Visionaries Club also participated in the round, as did former chairman and CEO of Johnson & Johnson Alex Gorsky and CEO and cofounder of Datadog Olivier Pomel.
WHAT IT DOES...
Multinational pharmaceutical and biotech company Pfizer and AI-powered data company Tempus announced a multiyear strategic alliance to utilize AI and machine learning to inform drug discovery and development in oncology.
Pfizer will leverage Tempus' library of de-identified data to accelerate therapeutic development in oncology. It will also use Tempus' AI-driven companion diagnostic offerings...
